Brandlistuen Ragnhild E, Ystrom Eivind, Hernandez-Diaz Sonia, Skurtveit Svetlana, Selmer Randi, Handal Marte, Nordeng Hedvig
Pharmacoepidemiology and Drug Safety Research Group, School of Pharmacy, PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
Norwegian Institute of Public Health, Oslo, Norway.
PLoS One. 2017 Jul 26;12(7):e0181042. doi: 10.1371/journal.pone.0181042. eCollection 2017.
During pregnancy, many women experience sleep problems and anxiety that require treatment. The long-term safety for the child of maternal benzodiazepine (BZD) and z-hypnotic use during pregnancy remains controversial.
We conducted a cohort and a sibling control study using data from the Norwegian Mother and Child Cohort Study. Data on use of BZD and z-hypnotics, internalizing and externalizing outcomes, and covariates were collected from mothers at gestational weeks 17 and 30 and when children were 0.5, 1.5, and 3 years of age. The total sample consisted of 71,996 children (19,297 siblings) at 1.5 years and 55,081 children (13,779 siblings) at 3 years. Short-term use was defined as use in one pregnancy period only. Long-term use was defined as use in two or more pregnancy periods. Linear full cohort random-effect and sibling-matched fixed-effect regression models were used to compare internalizing and externalizing behavior in children prenatally exposed compared to those unexposed in the full cohort of pregnancies accounting for family clusters, as well as within sibling clusters comparing pregnancies with discordant exposures. Propensity score (PS) adjustment included variables on indication for use (sleep problems, symptoms of anxiety and depression) and other potential confounding factors.
Long-term prenatal exposure to BZD or z-hypnotics was associated with increased internalizing behavior in crude cohort analyses and at age 1.5 years after PS adjustment in sibling-matched fixed-effect models [β 0.60, 95% confidence interval 0.17-0.95]. Analyses on specific drug groups showed that prenatal exposure to BZD-anxiolytics was associated with increased internalizing problems at both 1.5 years [β 0.25, 0.01-0.49] and 3 years [β 0.26, 0.002-0.52] while exposure to z-hypnotics was not associated with any adverse outcomes after adjustment.
The findings suggest a moderate association between BZD-anxiolytic exposure and child internalizing problems that is not likely due to stable familial confounding factors.
在孕期,许多女性会出现需要治疗的睡眠问题和焦虑症状。孕期母亲使用苯二氮䓬类药物(BZD)和Z类催眠药对孩子的长期安全性仍存在争议。
我们利用挪威母婴队列研究的数据进行了一项队列研究和一项同胞对照研究。在妊娠第17周和第30周以及孩子0.5岁、1.5岁和3岁时,收集母亲使用BZD和Z类催眠药的数据、内化和外化结果以及协变量。总样本包括1.5岁时的71996名儿童(19297对同胞)和3岁时的55081名儿童(13779对同胞)。短期使用定义为仅在一个孕期使用。长期使用定义为在两个或更多孕期使用。线性全队列随机效应模型和同胞匹配固定效应回归模型用于比较产前暴露组和未暴露组儿童在全队列妊娠中的内化和外化行为,同时在同胞组内比较暴露不同的妊娠。倾向得分(PS)调整包括使用指征(睡眠问题、焦虑和抑郁症状)和其他潜在混杂因素变量。
在粗略队列分析中,以及在同胞匹配固定效应模型中进行PS调整后,1.5岁时,产前长期暴露于BZD或Z类催眠药与内化行为增加相关[β 0.60,95%置信区间0.17 - 0.95]。对特定药物组的分析表明,产前暴露于BZD抗焦虑药在1.5岁[β 0.25,0.01 - 0.49]和3岁[β 0.26,0.002 - 0.52]时均与内化问题增加相关,而暴露于Z类催眠药在调整后未发现与任何不良结局相关。
研究结果表明,BZD抗焦虑药暴露与儿童内化问题之间存在中度关联,这不太可能是由于稳定的家族混杂因素导致的。